Picture loading failed.

Anti-IL12B therapeutic antibody (Pre-made Briakinumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-081-1mg 1mg 3090
GMP-Bios-ab-081-10mg 10mg 21890
GMP-Bios-ab-081-100mg 100mg 148000
GMP-Bios-ab-081-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL12B therapeutic antibody (Pre-made Briakinumab biosimilar,Whole mAb)
INN Name Briakinumab
TargetIL12B
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Preregistration (w)
Est. StatusDiscontinued
100% SI Structure5n2k:LK:BA:PO:DC:NM:FE
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesCambridge Antibody Technology;Abbott GmbH & Co. KG
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedPlaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis
Development Techna